Digitizing human biology.
All patients must have rapid access to personalized & affordable treatments.

Génèse - BM
The genesis of

• High-throughput & interoperable solutions
• Neurons, bio-digital sensors
• Digital Library

Towards a revolution in the regulatory environment

• Alternative method
• Toxicity & efficacy

futur - BM
Towards a revolution in pharmaceutical research

• Scientific
• Ethic
• Economic

OoC - BM
OoCs, in practice

• Accelerating drug development
• Saving cost

industrialisation - BM
NETRI, industrial start-up

• Pilot production unit - 230 m²
• 9 products on the market
• 70 customers


The genesis of NETRI.

Based on 10 years of academic research, NETRI was founded in June 2018 in Lyon at the heart of the Gerland biodistrict. Since 2018, NETRI has developed a unique value proposition on the organs-on-chip market. NETRI solutions offer to generate the level of data (throughput) and biological complexity (relevance) required to validate the predictive nature of compounds in humans, with 3 main areas of differentiation:

Towards a revolution in the regulatory environment.

The marketing of new treatments, whatever their field of application, requires testing of their toxicity and efficacy on physiological models prior to regulatory approval. The dermo-cosmetics, pharmaceutical and food health markets in particular are concerned by this regulatory framework. However, these three markets are not subject to the same regulatory constraints when it comes to bringing new molecules to market:

Towards a revolution in pharmaceutical research.

Healthcare industries developing treatments are looking for solutions to three structural challenges:

NETRI is convinced that the future of drug trials will focus on the rapid, replicable generation of large volumes of biological data (for artificial intelligence processing), generated with the increased translation offered by organs-on-chip (OoCs), helping to limit animal experimentation. In this context, NETRI addresses the dermo-cosmetics, pharmaceutical and food health markets to meet their specific challenges.

OoCs, in practice.

Organs-on-chip (OoCs) are microfluidic devices that enable human cells to be positioned and connected in the same way as in a healthy or diseased human body.

Organs-on-chip, imagined in 2011 by Professor Don Inberg and his lung-on-chip model, simulate the physiology of human body organs such as the brain, liver and heart. Historically positioned on neurological disorders, NETRI has enabled its customers to observe, through its technologies, curative effects of their molecules previously impossible to observe with conventional technologies.

By varying the connection architectures, it is possible to monitor, by pathology, the response of the neuronal network to new treatments by recording how neurons communicate with each other and with other cell types. NETRI positions itself within its ecosystem and in relation to its competitors as the only player enabling the innervation and vascularization of any organ, constituting a competitive advantage and a strategic barrier to entry for its direct competitors.

NETRI, industrial start-up.

After 4 years of research and development, NETRI has built solutions using neurons as sensors integrated into its high-throughput, interoperable solutions, enabling the construction of a digital library of references. These solutions are offered in the form of ready-to-use devices (dry devices or kits), services and SaaS software:


Discover our new exclusive package
organs-on-chip kits and all our
neuro-organs-on-chip devices.



Quickly and easily adopt organs-on-chip

into users’ research